ArticleScientific reports2025
Levels of the nicotine analog 6-methyl nicotine as a naturally formed tobacco alkaloid in tobacco and tobacco products.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Toxicity, Chemistry, and Public Health Relevance of Emerging Nicotine Analog Vapes, Pods, and Pouches.Chemical research in toxicology · 2026Review
- 6-Methyl nicotine and nicotine have similar thermoregulatory and reinforcing effects in middle aged female rats with a history of nicotine vapor self-administration.Pharmacology, biochemistry, and behavior · 2026Article
- Characterizing oxidative metabolites of 6-methylnicotine (6MN; aka Metatine): divergent metabolism from nicotine and identification of urinary biomarkers of exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2025Article
- A review of popular vaping misconceptions: redefining ENDS safety and usage risks.Inhalation toxicologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
S-6-methyl nicotine (S-6MN) has appeared as a nicotine substitute in commercial electronic e-cigarette products and pouches, including with the claim that such use is not regulated under current U.S. law. This work describes an analytical chemistry based search for the natural S/R presence of 6MN and three other MN compounds in additive-free cured leaf tobaccos and in multiple commercial tobacco products. The samples were extracted using 5 N NaOH, then methyl t-butyl ether. The extracts were analyzed using gas chromatography (GC) with mass spectrometric (MS) detection, and liquid chromatography (LC) with high resolution MS/MS detection. GC peaks with the correct retention times and MS patterns were found and confirmed for 6MN. Further confirmation for the presence of 6MN was obtained by LC/MS/MS. The all-sample average level of 6MN was determined to be 0.32 µg per g of tobacco material; the levels were too low to determine the S/R distributions. For 2MN, strong but not fully confirmed (*) evidence was obtained; analytical results are presented for 2MN* at an all-sample average level of 0.10 µg per g of tobacco material. No evidence for either 4MN nor 5MN was found. Because most commercial nicotine is as extracted and purified from tobacco, 6MN can be expected in all such nicotine, and therefore in most nicotine-containing e-cigarettes (ENDS) as well as reagent-grade nicotine. Analyses of GC/MS data from past analyses of nine high-nicotine e-cigarette liquids purchased during the period 2018 to 2022 indicated a mean ± 1 s.d. result for 6MN of 6.3 ± 1.4 µg/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.